March 17 (Reuters) - Candel Therapeutics Inc CADL.O:
CANDEL THERAPEUTICS INC: EXTENDED SURVIVAL TAIL OBSERVED IN TRIAL OF AGLATIMAGENE BESADENOVEC
CANDEL THERAPEUTICS INC: PHASE 3 PIVOTAL STUDY PLANNED FOR INITIATION IN Q2 2026
Source text: ID:nGNXc45RNl
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))